Immunotherapy News and Research RSS Feed - Immunotherapy News and Research

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
Researchers examine which condition comes first - childhood obesity or asthma?

Researchers examine which condition comes first - childhood obesity or asthma?

For years, doctors have known that there is a link between childhood obesity and asthma, but have found it difficult to determine which condition tends to come first, or whether one causes the other. [More]
LSDF announces $750,000 in Proof of Concept grants to promote health-related technologies

LSDF announces $750,000 in Proof of Concept grants to promote health-related technologies

The Life Sciences Discovery Fund (LSDF) today announced nearly $750,000 in Proof of Concept grants to Washington state for-profit and non-profit organizations to promote translation of health-related technologies from the laboratory to the commercial marketplace. [More]
Ludwig, CRI collaborate with VentiRx to conduct clinical trial with motolimod and immunotherapy agents

Ludwig, CRI collaborate with VentiRx to conduct clinical trial with motolimod and immunotherapy agents

The nonprofits Ludwig Cancer Research (Ludwig) and the Cancer Research Institute (CRI) announced today an agreement with VentiRx Pharmaceuticals Inc., a clinical stage biopharmaceutical company, to conduct a clinical trial with motolimod (VTX-2337) combined with other immunotherapy agents available to Ludwig and CRI through other industry partnerships. [More]
Scientists make important breakthrough in fight against debilitating autoimmune diseases

Scientists make important breakthrough in fight against debilitating autoimmune diseases

Scientists have made an important breakthrough in the fight against debilitating autoimmune diseases such as multiple sclerosis by revealing how to stop cells attacking healthy body tissue. [More]
Amgen seeks EMA approval for marketing talimogene laherparepvec

Amgen seeks EMA approval for marketing talimogene laherparepvec

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic. [More]
VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy. [More]
Researchers find method to expand blood stem cells used to treat cancer patients

Researchers find method to expand blood stem cells used to treat cancer patients

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. [More]
Vaccine boosts advanced NSCLC patient survival

Vaccine boosts advanced NSCLC patient survival

Investigation of a vaccine targeting a glycoside present in non-small-cell lung cancer has demonstrated efficacy as a switch therapy for patients with stable, advanced disease after chemotherapy. [More]

TxCell announces five new patents for core technology and ASTrIA platform

TxCell SA, a biotech developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, today announces that five new patents for their technologies have been issued in the Unites States, Asia and Australia since the beginning of 2014. [More]
Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans. [More]
Spring Bioscience launches PD-L1 (SP142) rabbit monoclonal immunohistochemistry antibody1

Spring Bioscience launches PD-L1 (SP142) rabbit monoclonal immunohistochemistry antibody1

Spring Bioscience (Spring), a member of the Roche Group, today announced the launch of its PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody. [More]
ESMO announces names of outstanding individuals receiving annual awards

ESMO announces names of outstanding individuals receiving annual awards

The European Society for Medical Oncology, the leading pan-European organisation representing medical oncologists, announced the names of outstanding individuals receiving the Society's esteemed annual awards, to be presented during the ESMO 2014 Congress, on 26 September, in Madrid. [More]
Natural killer cells can be used to combat acute lymphoblastic leukemia

Natural killer cells can be used to combat acute lymphoblastic leukemia

Researchers at Children's Hospital Los Angeles have shown that a select team of immune-system cells from patients with leukemia can be multiplied in the lab, creating an army of natural killer cells that can be used to destroy the cancer cells. [More]
Modified C. novyi-NT bacterium produces precisely targeted anti-tumor response

Modified C. novyi-NT bacterium produces precisely targeted anti-tumor response

A modified version of the Clostridium novyi (C. novyi-NT) bacterium can produce a strong and precisely targeted anti-tumor response in rats, dogs and now humans, according to a new report from Johns Hopkins Kimmel Cancer Center researchers. [More]
Researchers find priority targets for ovarian cancer immunotherapy

Researchers find priority targets for ovarian cancer immunotherapy

Researchers at Roswell Park Cancer Institute (RPCI) have found that the expression pattern of a unique class of tumor-associated antigens, known as the MAGE cancer-testis antigens (CTAs), correlates with clinical outcome in epithelial ovarian cancer. [More]
Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents

Oncothyreon acquires Alpine Biosciences to enable targeted delivery of multiple therapeutic agents

Oncothyreon Inc., a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it has acquired Alpine Biosciences, Inc., of Seattle, Washington, a privately held biotechnology company developing protocells, a nanoparticle platform technology designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides and small molecules. [More]
Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. [More]
New method could make cashews safer for people with allergies

New method could make cashews safer for people with allergies

For the millions of adults and children in the U.S. who have to shun nuts to avoid an allergic reaction, help could be on the way. Scientists are now developing a method to process cashews - and potentially other nuts - that could make them safer to eat for people who are allergic to them. [More]
Celsion announces financial results for second quarter ended 2014

Celsion announces financial results for second quarter ended 2014

Celsion Corporation, an oncology drug development company, today announced financial results for the second quarter ended June 30, 2014. [More]
Triple therapy for glioblastoma has prolonged survival of mice with brain cancers

Triple therapy for glioblastoma has prolonged survival of mice with brain cancers

A triple therapy for glioblastoma, including two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report by scientists at the Johns Hopkins Kimmel Cancer Center. [More]